- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02040376
Metformin för hjärnreparation hos barn med kranial-ryggradsstrålning för medulloblastom
Placebokontrollerad dubbelblind crossover-studie av metformin för hjärnreparation hos barn med kranial-ryggradsstrålning för medulloblastom
A placebo controlled double blind crossover trial of metformin in 30 children treated with radiation for medulloblastoma - the most common malignant brain tumour. The investigators used tests of thinking and learning and brain imaging techniques to examine whether metformin can enhance cognition or promote brain repair following radiation-induced brain injury.
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
We conducted a pilot randomized, double-blind, placebo-controlled trial with crossover in survivors of pediatric brain tumors with primary endpoints of safety and feasibility and secondary endpoints of cognitive and magnetic resonance imaging (MRI) measures. Twenty-four participants were enrolled and randomly assigned to complete 12-week cycles of metformin (A) and placebo (B) in either a group AB (AB) or group BA (BA) sequence. At the point of crossover, there was a 10-week washout period in which neither group received any treatment. During the first week of each treatment cycle, a daily dose of 500 mg/m2 of metformin or placebo was administered orally. The dose was increased to 1000mg/m2 daily beginning in the second week and continuing for the remainder of the 12-week cycle.
Test procedures (Clinical & current medications reviews, Blood draws, and MRI and Cognitive testing) were performed at 4 times points during the study: 1. at study entry (Baseline 1), 2. after 12 weeks of treatment (Outcome 1), 3. after a 10-week washout period at 22 weeks (Baseline 2), and 4. At the end of the trial at 34 weeks (Outcome 2).
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- The Hospital for Sick Children
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria: Survivors will be included if they:
-
Have been treated with cranial or cranial-spinal radiation,
-
Are between 5 and 21 years of age at time of consent, and
-
Either declare English as their native language or have had at least two years of schooling in English at the time of their baseline assessment.
-
Have been diagnosed with a brain tumour requiring treatment with cranial or cranial-spinal radiation at least 2 years ago, is not receiving active treatment and no more than 15 years may have elapsed between treatment with cranial-spinal radiation and time of the trial. Survivors with a shunt will be included in the trial, but will need to be identified prior to study enrollment to discuss any specific considerations for imaging.
-
Meet criteria for adequate organ function requirements:
-
Adequate renal function defined as: Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 70ml/min/1.73 m2 or serum creatinine based on age/gender as follows:
Maximum Serum Creatinine Level (mg/dL)
5 to < 10 years: Male = 1; Female = 1
10 to < 13 years: Male = 1.2; Female = 1.2
13 to < 16 years: Male = 1.5; Female = 1.4
≥ 16 years: Male = 1.7; Female = 1.4
-
Adequate liver function defined as:
Total bilirubin < 1.5 x upper limit of normal (ULN) for age, and,
serum glutamate oxaloacetate transaminase (SGOT) (AST) or serum glutamate pyruvate transaminase (SGPT) (ALT) < 3 x upper limit of normal (ULN) for age.
-
-
Females of childbearing potential must have a negative pregnancy test result and must agree to use a medically acceptable method of contraception throughout the entire study period and for 30 days after the last dose of study drug.
-
Informed consent will be obtained from the participants and/or their legal guardians by study team members authorized to consent for this study.
Exclusion criteria: Survivors will be excluded if they
- Are receiving palliative care.
- Are unable to participate in neuro-imaging without sedation as this is the primary outcome measure for the trial.
- Are unable to swallow tablets.
- Are unstable and/or insulin-dependent (Type 1) diabetic patients.
- Have acute or chronic metabolic acidosis and/or lactic acidosis.
- Any female patient or partner who has reached menarche and male patients who are not willing to use an effective method of contraception.
- Patient who is pregnant or lactating and does not agree to stop breastfeeding while receiving trial treatment.
- Have a history of renal disease or renal dysfunction e.g., as suggested by elevated serum creatinine levels (see 5.a. Inclusion criteria) or abnormal creatinine clearance.
- Have a history of congestive heart failure requiring pharmacologic treatment.
- Have a known hypersensitivity to metformin hydrochloride.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Group A (Crossover Group 1)
Subjects assigned to this arm will receive metformin first, followed by a washout period and then placebo. |
Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. |
|
Experimentell: Group B (Crossover Group 2)
Subjects assigned to this arm will receive placebo first, followed by a washout period and then metformin. |
Metformin doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. Placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Feasibility: Medication Adherence
Tidsram: Outcome 2 (Week 35)
|
Participant's adherence to taking study medication (Metformin or Placebo) as instructed based on dosing nomogram, for the whole study. % Medication adherence = (Number of tablets actually consumed / Number of tablets expected to be consumed)*100 Number of tablets actually consumed is based on compliance counts conducted at the end of the study. |
Outcome 2 (Week 35)
|
|
Safety: Frequency of Adverse Events (AE)
Tidsram: Outcome 2 (Week 35)
|
The frequency of all AEs experienced during metformin and placebo treatment for all participants. |
Outcome 2 (Week 35)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Cognitive Testing: Declarative Memory - Change in Children's Auditory Verbal Learning Test -2 (CAVLT-2)
Tidsram: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
For Arm AB:
For Arm BA:
|
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
|
Cognitive Testing: Working Memory - Change in List Sort Working Memory Subtest of the NIH Toolbox Cognition Battery
Tidsram: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)
|
For Arm AB:
For Arm BA:
|
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), Outcome 2 (Week 35)
|
|
Cognitive Testing: Processing Speed - Change in Mean Reaction Time across Cambridge Neuropsychological Test Automated Battery (CANTAB) subtests
Tidsram: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
Change in Mean Reaction Time (MRT) across the following CANTAB subtests:
Each subtest provides an outcome measure of response latency, which will be averaged across all correct trials for each subtest to provide an overall measure of processing speed. For Arm AB:
For Arm BA:
|
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Neuroimaging: MRI Measures of White Matter Growth within the Corpus Callosum
Tidsram: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
Change in Axonal Water Fraction (AWF)- Diffusion Kurtosis Imaging (DKI) metric sensitive to myelin |
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35)
|
|
Neuroimaging: MRI Measures of Hippocampal Volume
Tidsram: Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35
|
Change in Hippocampal Volume, as measured by Cerebral Blood Flow (CBF) |
Baseline 1 (Week 1), Outcome 1 (Week 13), Baseline 2 (Week 23), and Outcome 2 (Week 35
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Donald Mabbott, PhD, The Hospital for Sick Children
Publikationer och användbara länkar
Allmänna publikationer
- Ayoub R, Ruddy RM, Cox E, Oyefiade A, Derkach D, Laughlin S, Ades-Aron B, Shirzadi Z, Fieremans E, MacIntosh BJ, de Medeiros CB, Skocic J, Bouffet E, Miller FD, Morshead CM, Mabbott DJ. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med. 2020 Aug;26(8):1285-1294. doi: 10.1038/s41591-020-0985-2. Epub 2020 Jul 27.
- Baudou E, Ryan JL, Tseng J, Bouffet E, Bartels U, Timmons BW, de Medeiros CB, Mabbott DJ. Repairing Myelin After Irradiated Pediatric Brain Tumor: A Magnetization Transfer Imaging Analysis. Pediatr Blood Cancer. 2025 Sep;72(9):e31838. doi: 10.1002/pbc.31838. Epub 2025 Jun 14.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer, körtel och epitel
- Gliom
- Neoplasmer, neuroepitelial
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroektodermala tumörer, primitiva
- Medulloblastom
- Organiska kemikalier
- Biguanider
- Guanidiner
- Amidiner
- Metformin
Andra studie-ID-nummer
- 1000039383
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .